Evolve Short DAPT

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Evolve Short DAPT [NCT02605447]

Description: The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.

Drug: 3 months of dual antiplatelet therapy (DAPT); Device: SYNERGY Stent System

Primary Investigator: Kereiakes

Drug/Device Information
To assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the Synergy Stent System
Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System
Subjects are eligible for discontinuation of P2Y12 inhibitor at 3 months if they meet both of the following criteria (A and B)
A. Subject was treated with 3 months of P2Y12 inhibitor/aspirin post index procedure
B. Subject was free from events (stroke, MI, PCI, CABG, and stent thrombosis) between the index procedure and the 3 month visit
Nonrandomized
Boston Scientific Corporation